Quadrant Capital Group LLC Global Blood Therapeutics, Inc. Transaction History

Quadrant Capital Group LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$22.3 - $37.39 $557 - $934	-25 Reduced 47.17%	28 $1,000
Q1 2022 May 06, 2022	SELL	$25.68 - $35.59 $102 - $142	-4 Reduced 7.02%	53 $2,000
Q4 2021 Feb 01, 2022	BUY	$24.9 - $40.26 $722 - $1,167	29 Added 103.57%	57 $2,000
Q3 2021 Nov 12, 2021	BUY	$25.48 - $37.34 $713 - $1,045	28 New	28 $1,000
Q2 2021 Aug 09, 2021	SELL	$32.46 - $43.42 $97 - $130	-3 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$37.65 - $63.77 $640 - $1,084	-17 Reduced 85.0%	3 $0
Q3 2020 Nov 13, 2020	BUY	$52.76 - $74.49 $1,055 - $1,489	20 New	20 $1,000
Q2 2020 Aug 13, 2020	SELL	$48.73 - $81.82 $146 - $245	-3 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$41.72 - $87.2 $125 - $261	3 New	3 $0
Q3 2019 Oct 24, 2019	SELL	$45.35 - $57.91 $15,736 - $20,094	-347 Closed	0 $0
Q2 2019 Jul 24, 2019	BUY	$52.6 - $63.29 $18,252 - $21,961	347 New	347 $18,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.